FirstWord HealthTech’s Post

Discover the transformative role of Artificial Intelligence in Oncology! Explore insights from Mr. Dinesh Chauhan, CŌRE of CORE Diagnostics, on how AI is revolutionizing cancer diagnosis, treatment, and research. Read more at : https://lnkd.in/gYWzYynM

"University of Oxford researchers have leveraged the power of artificial intelligence (AI) to develop personalized cancer treatments which could be more effective at preventing patient relapse. One of the greatest challenges in cancer treatment is maximizing the impact for the patient from drug treatments. Conventional treatment strategies, which focus on killing as many cells as possible, are based on a 'maximum tolerated dose' (MTD) therapy, where the patient continually receives a high drug dose, with no breaks in treatment. However, these frequently fail against metastatic cancers due to the emergence of drug resistance." #ai #cancer #oncology

ICYMI: ElmediX: Up To Є5 Million For Series A Following Strong Signals In Pancreatic Cancer Patient Clinical Study

Why should ctDNA analysis be included in oncology clinical trials? CtDNA (circulating tumor DNA) analysis brings several unique advantages to clinical trials. These advantages stem from ctDNA's ability to provide real-time, non-invasive snapshots of a patient's tumor dynamics, offering insights that were previously difficult or impossible to obtain. Here are the key benefits of using ctDNA analysis in clinical trials: 1. Non-Invasive Sampling Patient Comfort: Unlike traditional biopsy methods, ctDNA analysis does not require invasive procedures to collect tumor tissue. This makes participation in clinical trials more appealing to patients, potentially increasing enrollment rates. 2. Real-Time Monitoring Dynamic Assessment: CtDNA can be measured from blood samples collected at various times throughout a clinical trial, allowing for real-time monitoring of tumor dynamics. This capability enables researchers to assess the efficacy of treatments more quickly and accurately than traditional methods. 3. Early Detection of Resistance Mechanism Identification: By tracking changes in ctDNA levels and sequences, researchers can identify when and how a tumor develops resistance to a particular treatment. This insight can lead to adjustments in treatment strategies, potentially improving patient outcomes. 4. Personalized Treatment Approaches Tailored Therapies: The genetic information contained in ctDNA can inform personalized treatment approaches. By identifying specific genetic alterations in a patient's tumor, researchers can match them with targeted therapies that are more likely to be effective. 5. Reduced Bias in Biomarker Evaluation Objective Measurement: CtDNA analysis provides an objective measure of tumor burden and treatment response, reducing bias that can arise from subjective assessments or variations in imaging interpretation. 6. Cost-Effective Operational Efficiency: Compared to some other methods, ctDNA analysis can be more cost-effective, especially when considering the reduced need for invasive procedures and the potential for automation and standardization of sample processing. 7. Facilitates Adaptive Trials Adaptability: The ability to monitor ctDNA levels in real-time supports the design of adaptive clinical trials, where treatment strategies can be adjusted based on intermediate endpoints. This adaptability can accelerate the development of effective therapies. 8. Enhances Patient Engagement Transparency and Participation: Providing patients with updates on their ctDNA levels can enhance transparency and engagement in their own care. This approach can foster a sense of shared decision-making and empowerment . In summary, ctDNA analysis offers significant advantages in clinical trials, from enhancing patient comfort and engagement to facilitating real-time monitoring and personalized treatment approaches. These benefits underscore the growing importance of ctDNA analysis. Learn more on www.simsendiagnostics.com

More oncology studies in the Pipeline

AI is also helping radiologists analyse mammograms which together with this will lead to earlier breast cancer diagnoses. At the same time it is enabling breakthroughs in drug design to treat advanced or metastatic cancer which will improve patient outcomes for those with stage IV cancer. #artificialintelligence #diagnosis #treatment #beastcancer #paitientoutcomes #health

The next CCO #PaperOfTheWeek comes to us from PLOS Computational Biology, where MingYi Wang, Jacob Scott, and Alexander Vladimirsky (https://lnkd.in/gFhh9rYR) have written on "Threshold-awareness in adaptive cancer therapy". Their study proposes a method to select optimal adaptive treatment plans that accounts for evolving tumor dynamics. Consider checking it out! --> Here's the link: https://lnkd.in/g5YfmHtA

Precision medicine is transforming #cancer care, tailoring treatments to individual genetics and tumor specifics. From novel CAR T cell therapies to targeted #immunotherapies, it promises more effective, personalized care. Discover how this innovative approach is shaping the future of oncology. https://ow.ly/8KfU50QATjg

[#ASCO24] Lunit Cancer Screening's AI-powered software, presented at the ASCO 2024 Annual Meeting, marks a significant advancement in detecting HER2 ultralow levels in breast cancer. This technology enhances patient selection for targeted therapies like #Enhertu, which has shown remarkable efficacy for HER2-low patients. Dr. Chang Ho Ahn, Lunit’s Medical Director, detailed how their AI model identifies HER2 expression with unprecedented precision, potentially benefiting more patients previously deemed ineligible for HER2-targeted treatments. Stay tuned for more updates on this game-changing development in #oncology. #medicalAI #digitalhealth American Society of Clinical Oncology (ASCO) Lunit Oncology https://lnkd.in/gxNruyUx

Publication out from our work with Ajou Medical Center! Real world use of CancerVision TE-WGS. (A) 72% actionabiliy (B) 11 days median turnaround time Fully validated with CAP/CLIA. It’s whole genome. It gives you everything about the patient’s cancer genome. #inocras #wholegenomesequencing #bioinformatics #cancer #ngs #precisiononcology #cancervision